Congestive Heart Failure (CHF)
CHF is a chronic, progressive condition in which the heart is unable to supply sufficient blood and oxygen to the body. It can result from conditions that weaken the heart muscle, cause stiffening of the heart muscles, or increase oxygen demand by the body tissues beyond the heart’s capability.
Cardiovascular disease is the leading cause of death worldwide, with known CHF affecting an estimated 1–2 percent of adults in developed countries, including over six million Americans. There is no cure, and medications and surgical treatments only seek to relieve symptoms and reduce further damage.
Research suggests one possible cause leading to CHF may be protein phosphatase inhibitor 1 ( I-1c) being down-regulated in failing hearts. Gene therapy is being investigated as an approach to treat CHF based on its potential to improve heart function.
Visit the National Institutes of Health website to learn more about CHF.
CHF Advocacy Partners
We are fortunate to work with patient advocacy groups, as well as leading researchers, scientists, and medical professionals to bring new therapeutics for CHF into the clinic. These include:
Clinical Trials
Patients who can benefit from promising gene therapeutics may suffer an altered way of life. As many diseases are progressive, AskBio is committed to advancing and developing gene therapies that could benefit patients.
